Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial for the Treatment of Relapsed Osteosarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of high grade osteosarcoma recurrence~* Resectable or unresectable recurrence disease within 24 months from the initial diagnosis~* Pleuro-pulmonary recurrence with more than 2 nodules within 24 months from the initial diagnosis~* Unresectable first relapse within 24 months from the initial diagnosis~* Resectable or unresectable second of further recurrence of high grade osteosarcoma~* Age at diagnosis at least 4years.~* Karnofsky performance status over 60%.~* Renal function and hepatic In normal limits for age.~* L eft ejection ventricular fraction over 50%.~* White blood cells over 3000 million/liter and platelets 100000 million/liter~* Birth potential female must agreed to contraception~* Signed written informed consent~Exclusion Criteria:~* Contraindication to the use of any study drugs~* Mental, social and geographic conditions which fail to ensure adequate adherence to the study~* Hepatitis and human immunodeficiency virus active infection~* Pregnancy or breast-feeding~* Previous treatment with Gemcitabine, Docetaxel and Ifosfamide

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine and Docetaxel (Type: EXPERIMENTAL): Gemcitabine i.v. 900 mg/m2 in 30 min on day 1 and day 8 every 3 weeks Docetaxel i.v. 75 mg/m2 in 60 min on day 8 every 3 weeks
- Ifosfamide (Type: EXPERIMENTAL): Ifosfamide i.v. 14 g/m2 continous dose for 14 days every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).